Medpace Holdings, Inc. (NASDAQ:MEDP) Stake Raised by Xponance Inc.

Xponance Inc. grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,177 shares of the company’s stock after buying an additional 171 shares during the period. Xponance Inc.’s holdings in Medpace were worth $1,720,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in MEDP. Proficio Capital Partners LLC increased its stake in shares of Medpace by 34,497.4% during the fourth quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company’s stock valued at $80,575,000 after acquiring an additional 241,827 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Medpace during the fourth quarter valued at approximately $78,144,000. Iron Triangle Partners LP acquired a new position in shares of Medpace during the third quarter valued at approximately $64,371,000. GW&K Investment Management LLC increased its stake in shares of Medpace by 93.9% during the fourth quarter. GW&K Investment Management LLC now owns 275,460 shares of the company’s stock valued at $91,516,000 after acquiring an additional 133,379 shares during the period. Finally, Wellington Management Group LLP increased its stake in shares of Medpace by 36.0% during the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after acquiring an additional 109,886 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

NASDAQ MEDP opened at $324.23 on Friday. The stock has a market capitalization of $9.88 billion, a P/E ratio of 25.67, a P/E/G ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 1 year low of $302.01 and a 1 year high of $459.77. The business’s fifty day moving average is $337.72 and its two-hundred day moving average is $339.82.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird raised their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Medpace currently has an average rating of “Hold” and an average target price of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.